A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Trial Profile

A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Lemborexant (Primary) ; Suvorexant; Zolpidem
  • Indications Insomnia
  • Focus Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 18 Sep 2017 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.
    • 18 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
    • 25 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top